KG
Therapeutic Areas
LENZ Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| LNZ100 (aceclidine) | Presbyopia | Phase 3 |
| LNZ101 (aceclidine + brimonidine) | Presbyopia | Phase 3 |
Leadership Team at LENZ Therapeutics
ES
Eef Schimmelpennink
President and Chief Executive Officer
M(
M. (Rienk) van Genderingen
Chief Financial Officer
RK
Raj K. Gupta
Chief Development Officer
MO
Marc Odrich
Chief Medical Officer
S(
Sunil (Sunny) Patel
Chief Business Officer
PE
Patrick Enright
Chairman of the Board
JT
Juliet Tammenoms Bakker
Director
DW
David W. J. McGirr
Director
TP
Timothy P. Walbert
Director